Travere Therapeutics (TVTX) P/B ratio
Travere Therapeutics (TVTX) trades at 39.7× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 29.7×. That is 27.6% higher than the 23.3× of fiscal 2024. Figures as of 18 Nov 2026, 09:36 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/B ratio today
- 39.7×
- P/B ratio, fiscal 2025
- 29.7×
- Change on fiscal 2024
- +27.6%
- Highest on record
- 31.3×fiscal 2022
- Lowest on record
- 2.4×fiscal 2016
- Fiscal years on record
- 112015–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Travere Therapeutics P/B ratio, in more detail
Today's figure is 33.7% above the fiscal 2025 year-end.
Across the 11 fiscal year-ends on record (2015–2025), the highest was 31.3× in fiscal 2022 and the lowest 2.4× in fiscal 2016. Today's P/B ratio is above every one of the 11 fiscal year-ends on record; their median is 3.3×.
P/B ratio at each fiscal year-end
The last point is today's figure; the others are fiscal year-ends.
Travere Therapeutics P/B ratio, year by year
| Fiscal year | P/B ratio | Change | Year ended | Share price at year-end | Book value per share |
|---|---|---|---|---|---|
| Today | 39.7× | — | $51.10 | — | |
| 2025 | 29.7× | 27.6% up | $38.21 | $1.29 | |
| 2024 | 23.3× | 599.6% up | $17.42 | $0.75 | |
| 2023 | 3.3× | 89.4% down | $8.99 | $2.70 | |
| 2022 | 31.3× | 409.0% up | $21.03 | $0.67 | |
| 2021 | 6.1× | 0.2% up | $31.04 | $5.05 | |
| 2020 | 6.1× | 125.7% up | $27.25 | $4.44 | |
| 2019 | 2.7× | 5.5% down | $14.20 | $5.22 | |
| 2018 | 2.9× | 3.2% up | $22.63 | $7.87 | |
| 2017 | 2.8× | 18.3% up | $21.07 | $7.56 | |
| 2016 | 2.4× | 2.6% down | $18.93 | $8.04 | |
| 2015 | 2.4× | — | $19.29 | $7.98 | |
| 2014 | — | — | $12.24 | -$1.49 | |
| 2013 | — | — | $7.00 | -$1.38 | |
| 2012 | — | — | $3.35 | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.
How to read it
It compares the price with the accounting value of what the company owns net of what it owes, and matters most for banks, insurers and other balance-sheet businesses.
Travere Therapeutics, figure by figure
- Travere Therapeutics market cap
- Travere Therapeutics revenue
- Travere Therapeutics earnings
- Travere Therapeutics earnings per share (EPS)
- Travere Therapeutics P/E ratio
- Travere Therapeutics P/S ratio
- Travere Therapeutics free cash flow
- Travere Therapeutics operating margin
- Travere Therapeutics dividend
- Travere Therapeutics shares outstanding
- Travere Therapeutics total debt
- Travere Therapeutics cash on hand
- Travere Therapeutics total assets
- Travere Therapeutics return on equity (ROE)
- Travere Therapeutics return on invested capital (ROIC)
Travere Therapeutics (TVTX) overview: price, valuation and scorecardAll health care companies by market value
Travere Therapeutics P/B ratio: questions and answers
What is Travere Therapeutics's P/B ratio?
Travere Therapeutics (TVTX) trades at 39.7× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 29.7×. That is 27.6% higher than the 23.3× of fiscal 2024.
Is Travere Therapeutics's P/B ratio high or low compared with its own history?
Today's P/B ratio is above every one of the 11 fiscal year-ends on record; their median is 3.3×.
What are the highest and lowest P/B ratio figures on record for Travere Therapeutics?
Across the 11 fiscal year-ends on record (2015–2025), the highest was 31.3× in fiscal 2022 and the lowest 2.4× in fiscal 2016.
How is Travere Therapeutics's P/B ratio calculated?
The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B. For Travere Therapeutics it is on record here for 11 fiscal years, 2015 to 2025.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/B ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Piotroski F-score: the nine tests and what they show
The Piotroski F-score is a 0–9 count of simple accounting tests a company passes: four on profitability, three on debt, liquidity and share issuance, two on operating efficiency. Joseph Piotroski's 2000 paper found that among cheap, high book-to-market stocks, high scorers went on to beat low scorers. It is a screen of financial health, not a valuation.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Travere Therapeutics (TVTX) P/B ratio”, data as of 18 November 2026. https://funkfolio.com/stock/TVTX/pb-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.